These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Author: Weinberg JM, Tutrone WD.
    Journal: Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629.
    Abstract:
    During the past several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. The first article of this 2-part update reviewed the tumor necrosis factor (TNF) inhibitors, infliximab and etanercept. In this article, we will review 2 therapies that target the T cell, efalizumab and alefacept.
    [Abstract] [Full Text] [Related] [New Search]